JAK2 and lung carcinoma: MYC downregulates H3K27 acetylation and JAK2 expression, impairing the IFN-γ signaling pathway and rendering lung cancer cells resistant to PD1/PD-L1 therapy (Alburquerque-Bejar et al., 2023).